Key takeaways for Virginia
- • No GLP-1 is FDA-approved for PCOS — entirely off-label.
- • BMI 27+ may qualify under standard Wegovy/Zepbound labels if comorbidities present.
- • Improvements seen in insulin resistance, weight, and androgens; fertility data limited.
- • Cardinal Care (formerly Medallion + CCC Plus) coverage rules apply for PCOS (Polycystic Ovary Syndrome) patients in Virginia — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for PCOS (Polycystic Ovary Syndrome)
No GLP-1 is FDA-approved specifically for PCOS. However, small randomized trials and observational studies show GLP-1 RAs improve insulin sensitivity, support 5-15% weight loss, reduce free testosterone, and may improve menstrual regularity and ovulation. Evidence grade: C-B (smaller trials, growing evidence base). PCOS guidelines (ESHRE/Monash 2023) recognize obesity-targeted pharmacotherapy as adjunct. Patients trying to conceive should stop GLP-1s at least 2 months before pregnancy attempts.
Virginia-specific context
Virginia has telehealth access concentrated in Virginia Beach, Norfolk, Chesapeake metros, with additional reach to Richmond and Arlington. VCU Health, Inova Health System, Sentara Healthcare is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.vdh.virginia.gov.
Virginiatelehealth & pricing rules
- • Virginia permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • Virginia allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Virginia: ~$269/mo (compounded options often lower, brand higher).